-
December 2022 Market Access news recap
The monthy 3 minutes of selected bits of news: 62 seconds on DiPAs – digital care and nursing applications are launching in Germany Microbiome product Rebyota is now approved in the US – we are keenly watching out for access, uptake and reimbursement learnings… AIFA reimbursement committees merge Germany rare disease medicine Brineura to recevie…
-
November Market Access news recap
November market access news recap For the November recap a few news snippets from the pharma and digital health world: RWE collection in Germany, the Hemgenix gene therapy, early value assessment in England as well as the dynamic French digital health policy landscape. … as usual, three minutes of your time …
-
October Market Access news: HTA & pricing policy updates
This news update has a bit of a theme: HTA and reimbursement policies. There are a few reforms and regulation changes on-going across European markets, not to forget the preparations for the joint European HTA efforts through the Joint Clinical Assessment. Take three minutes to get on top of the latest updates.
-
France PLFSS 2023: Social security financing bill puts pressure on medicine pricing
France PLFSS 2023: Social security financing bill puts pressure on medicine pricing The draft of the French social security financing law for the year to come (PLFSS 2023) includes a few proposals that could have an impact on innovative medicine pricing, including ATMPs and products eligible for the “European price”, meaning products that have demonstrated…
-
August & September 2022 Market Access news recap
After the summer break, let’s quickly catch-up with selected August and September news from the access and reimbursement sphere….
-
July 2022 Market Access news recap
Three minutes selected reimbursement and pricing news from July, including the latest updates on the reform of German AMNOG early benefit assessment & pricing process.
-
Germany: Changes to innovative drug pricing and AMNOG ahead?
The first draft of the GKV finance stabilization act (GKV FinStG) has just been presented and holds tough news for industry. An outline of the key pricing and AMNOG changes proposed: The schedule for the further consultations on the law is not yet clear. Industry has already heavily critised the draft, seeing innovation not sufficiently rewarded…
-
June market access news recap
Three minutes to spare? Selected news from the last month. This time from NICE and the G-BA…